dr hab. Agnieszka Nikiforuk

dr hab. Agnieszka Nikiforuk

+48 12 6623374
pokój 27
Zakład Badań Nowych Leków

Dokonania naukowe

  • Publikacje

Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.

Autorzy: Zajdel P, Kos T, Marciniec K, Satała G, Canale V, Kamiński K, Hołuj M, Lenda T, Koralewski R, Bednarski M, Nowiński L, Wójcikowski J, Daniel WA, Popik P

DOI: 10.1016/j.ejmech.2018.01.002
Date: 2018-01-01

A Novel Dopamine Transporter Inhibitor CE-123 Improves Cognitive Flexibility and Maintains Impulsivity in Healthy Male Rats.

Autorzy: Nikiforuk A, Kalaba P, Ilic M, Korz V, Dragačević V, Wackerlig J, Langer T, Höger H, Golebiowska J, Popik P, Lubec G

DOI: 10.3389/fnbeh.2017.00222
Date: 2017-11-01

Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.

Autorzy: Koola MM, Sklar J, Davis W, Nikiforuk A, Meissen JK, Sawant-Basak A, Aaronson ST, Kozak R

DOI: 10.1016/j.schres.2017.07.005
Date: 2017-07-01

Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in a ketamine-based animal model of schizophrenia.

Autorzy: Zurawek D, Salerno-Kochan A, Dziedzicka-Wasylewska M, Nikiforuk A, Kos T, Popik P

DOI: 10.1016/j.schres.2017.04.014
Date: 2017-04-01

Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.

Autorzy: Potasiewicz A, Nikiforuk A, Hołuj M, Popik P

DOI: 10.1177/0269881116675509
Date: 2016-11-01

3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.

Autorzy: Potasiewicz A, Hołuj M, Kos T, Popik P, Arias HR, Nikiforuk A

DOI: 10.1016/j.neuropharm.2016.10.002
Date: 2016-10-01

The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.

Autorzy: Nikiforuk A, Potasiewicz A, Kos T, Popik P

DOI: 10.1016/j.bbr.2016.07.023
Date: 2016-07-01

The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors.

Autorzy: Nikiforuk A, Potasiewicz A, Rafa D, Drescher K, Bespalov A, Popik P

DOI: 10.1097/fbp.0000000000000201
Date: 2016-06-01

The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia.

Autorzy: Nikiforuk A, Hołuj M, Kos T, Popik P

DOI: 10.1016/j.neuropharm.2016.01.035
Date: 2016-01-01

Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia.

Autorzy: Nikiforuk A

DOI: 10.2174/1381612822666160127113758
Date: 2016-01-01

Zobacz także